Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies
Summary
The purpose of this phase II trial is to evaluate how well ATR kinase inhibitor AZD6738 works alone or in combination with olaparib in treating patients with renal cell carcinoma, urothelial carcinoma, pancreatic ductal adenocarcinoma, or other solid tumors that have spread to nearby tissue or lymph nodes or other parts of the body.
General Information
NCT#: NCT03682289
Study ID: 189510
Trial Phase: Phase II
Trial Sponsor: AstraZeneca, University of California, San Francisco (UCSF)
Therapies Used in This Trial: Olaparib, AZD6738